Schizophrenia — A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
Citation(s)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Nonsmokers